I’m convinced that this whole end point thing is just a replay of what happens in June of 2013, in agreement with you...except....we have so much more information in collateral areas that hadn’t even been thought about back then.

Bottom Line: We’re kicking a dead horse as the FDA has made it abundantly clear that they want Lipitor PLUS Crestor in the mix. Therefore it appears to me that our chance to move forward will be to look at all the areas..inflammation, kidney..etc the list goes on.....BUT...

we need vast infusions of cash at strategic times to fund all of this...that’s why we need someone else to pay for in return for a bargain basement deal for the company. Our best time, over the near term will be at the AHA in November...In the meantime it would be great to hold these current prices.